pamrevlumab (FG-3019) / FibroGen  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pamrevlumab (FG-3019) / FibroGen
MISSION, NCT02606136 / 2023-000321-80: Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Terminated
2
21
US
Pamrevlumab, Monoclonal Antibody to Connective tissue growth factor (CTGF), FG-3019
FibroGen, FibroGen, Inc.
Duchenne Muscular Dystrophy
05/20
08/23
2020-001472-14: Efficacy of pamrevlumab, a connective tissue growth factor monoclonal antibody, in patients with SARS-COV-2 infection.

Not yet recruiting
2
68
Europe
Pamrevlumab, FG-3019, Infusion
Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani”, FibroGen, Inc.
Patients with documented SARS-CoV-2 infection, Patients with documented SARS-CoV-2 infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 

Download Options